It's clear that there are multiple trials to consider in the name of brain cancer, some of them more recognized than others. However, it's clear that most of them are done over an extended stretch of time, seeing as how details are going to have to be picked up on. I feel as though this is for the best, seeing as how you can't exactly learn much over a day's time. This is especially true when considering the lengthy nature of study of the ETS2101 drug.
The Wall Street Journal posted an article in regards to the ETS2101 trial, which has entailed a number of patients affected with either primary or secondary brain cancer. Each of them was given a particular dose of ETS2101. This was done in order to see how well their bodies would take to it and if they would need larger or smaller amounts. The study will be done through 2014 as well, which means that organizations along the lines of Voices against Brain Cancer should bring their attention towards it.
Of course, you may stop and wonder what exactly ETS2101 is. The article spoke about it and it's been said that it a drug commonly utilized in order to treat patients with trauma. Thanks to pharmacology, though, it's been believed that this drug can actually prove useful for the sake of helping cancer patients, too. Two studies are being done, one with primary cancer patients and the other entailing secondary cancer patients. To say that there has been quite a bit of time invested here would be an understatement.
With this procedure being done, the report spoke about how patients were given heavier doses of the drug with time before tolerated level has been arrived at. In addition, fifteen patients have successfully completed the study, each of them receiving the right amounts of ETS2101 in relation to their body weight. With their tumors not responding objectively to the drug, there has been success on the matter. One can only imagine just how much stronger the results can prove to be in the long run.
It's easy to understand why these particular studies are done over the course of time, whether it is a matter of a few months or even a few years. Brain cancer is one of the most serious conditions and, as a result, a tremendous amount of focus is brought to the idea of treatment in the long run. Hopefully there is more work done with the ETS2101 drug set in place. In my opinion, there is a world of knowledge to pick up on here.
The Wall Street Journal posted an article in regards to the ETS2101 trial, which has entailed a number of patients affected with either primary or secondary brain cancer. Each of them was given a particular dose of ETS2101. This was done in order to see how well their bodies would take to it and if they would need larger or smaller amounts. The study will be done through 2014 as well, which means that organizations along the lines of Voices against Brain Cancer should bring their attention towards it.
Of course, you may stop and wonder what exactly ETS2101 is. The article spoke about it and it's been said that it a drug commonly utilized in order to treat patients with trauma. Thanks to pharmacology, though, it's been believed that this drug can actually prove useful for the sake of helping cancer patients, too. Two studies are being done, one with primary cancer patients and the other entailing secondary cancer patients. To say that there has been quite a bit of time invested here would be an understatement.
With this procedure being done, the report spoke about how patients were given heavier doses of the drug with time before tolerated level has been arrived at. In addition, fifteen patients have successfully completed the study, each of them receiving the right amounts of ETS2101 in relation to their body weight. With their tumors not responding objectively to the drug, there has been success on the matter. One can only imagine just how much stronger the results can prove to be in the long run.
It's easy to understand why these particular studies are done over the course of time, whether it is a matter of a few months or even a few years. Brain cancer is one of the most serious conditions and, as a result, a tremendous amount of focus is brought to the idea of treatment in the long run. Hopefully there is more work done with the ETS2101 drug set in place. In my opinion, there is a world of knowledge to pick up on here.
About the Author:
Visit Voices Against Brain Cancer if you're searching for some more information about glioblastoma and brain cancer awareness.
No comments:
Post a Comment